EGFR and non-small cell lung carcinoma: The California Cancer Consortium completed a phase II study of 37 patients with NSCLC and an EGFR mutation who had progressed on prior EGFR TKI therapy using the combination dose of 40 mg qd for cabozantinib and 150 mg qd for erlotinib [29].